Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates

Editas Medicine (EDIT) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.55 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 1.32%. A quarter ago, it was expected that this genome editing company would post a loss of $0.69 per share when it actually produced a loss of $0.82, delivering a surprise of -18.84%. Over the last four quarters, the comp ...